文献速递肝病

PNPLA3基因型与糖尿病可识别非酒精性脂肪性肝病中肝硬化高风险患者

PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis.
PubMed 文献 · Gastroenterology · 2023-02-07

研究纳入MGI和UKBB两个独立队列中非酒精性脂肪性肝病患者,采用Fine-Gray竞争风险模型分析遗传变异和代谢合并症与肝硬化发生的关系。结果显示PNPLA3-rs738409-GG基因型与糖尿病、肥胖、ALT≥2倍正常上限均与肝硬化发病率升高相关,且PNPLA3-rs738409-GG与临床危险因素有累加效应。在FIB4不确定风险(1.3-2.67)患者中,合并糖尿病和PNPLA3-rs738409-GG基因型者肝硬化发病率与FIB4高风险(>2.67)者相当,且为糖尿病但CC/CG基因型者的2.9-4.8倍。

要点

  • PNPLA3-rs738409-GG基因型、糖尿病、肥胖、ALT≥2倍正常上限均与肝硬化发病率升高相关。
  • FIB4 1.3-2.67且合并糖尿病和PNPLA3-rs738409-GG者肝硬化风险与FIB4>2.67者相当。
  • FIB4<1.3者肝硬化发病率显著低于FIB4>2.67者,即使存在临床危险因素和高危PNPLA3基因型。

核心结论

  • PNPLA3-rs738409基因型和糖尿病可识别目前被认为不确定风险(FIB4 1.3-2.67)但肝硬化风险与高风险(FIB4>2.67)者相似的非酒精性脂肪性肝病患者。
  • PNPLA3基因分型可能改善预后评估并有助于优先安排强化干预。

研究设计与样本

  • 研究纳入来自Michigan Genomics Initiative(MGI)和UK Biobank(UKBB)两个独立队列的参与者,非酒精性脂肪性肝病定义为丙氨酸氨基转移酶(ALT)升高且无其他慢性肝病。
  • 主要预测因素为与肝硬化相关的遗传变异和代谢合并症,采用Fine-Gray竞争风险模型进行时间-事件分析。
  • MGI纳入7893名参与者,UKBB纳入46880名参与者。

主要发现

  • 在单变量分析中,PNPLA3-rs738409-GG基因型、糖尿病、肥胖和ALT≥2倍正常上限在MGI和UKBB两个队列中均与肝硬化发病率升高相关。
  • PNPLA3-rs738409-GG与包括糖尿病、肥胖和ALT升高在内的临床危险因素具有累加效应。
  • 在纤维化-4(FIB4)评分不确定(1.3-2.67)的患者中,合并糖尿病和PNPLA3-rs738409-GG基因型者的肝硬化发病率与FIB4高风险评分(>2.67)者相当,且为合并糖尿病但CC/CG基因型者的2.9-4.8倍。
  • FIB4<1.3与肝硬化发病率显著低于FIB4>2.67相关,即使存在临床危险因素和高危PNPLA3基因型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) can progress to cirrhosis and hepatic decompensation, but whether genetic variants influence the rate of progression to cirrhosis or are useful in risk stratification among patients with NAFLD is uncertain. METHODS: We included participants from 2 independent cohorts, they Michigan Genomics Initiative (MGI) and UK Biobank (UKBB), who had NAFLD defined by elevated alanine aminotransferase (ALT) levels in the absence of alternative chronic liver disease. The primary predictors were genetic variants and metabolic comorbidities associated with cirrhosis. We conducted time-to-event analyses using Fine-Gray competing risk models. RESULTS: We included 7893 and 46,880 participants from MGI and UKBB, respectively. In univariable analysis, PNPLA3-rs738409-GG genotype, diabetes, obesity, and ALT of ≥2× upper limit of normal were associated with higher incidence rate of cirrhosis in both MGI and UKBB. PNPLA3-rs738409-GG had additive effects with clinical risk factors including diabetes, obesity, and ALT elevations. Among patients with indeterminate fibrosis-4 (FIB4) scores (1.3-2.67), those with diabetes and PNPLA3-rs738409-GG genotype had an incidence rate of cirrhosis comparable to that of patients with high-risk FIB4 scores (>2.67) and 2.9-4.8 times that of patients with diabetes but CC/CG genotypes. In contrast, FIB4 <1.3 was associated with an incidence rate of cirrhosis significantly lower than that of FIB4 of >2.67, even in the presence of clinical risk factors and high-risk PNPLA3 genotype. CONCLUSIONS: PNPLA3-rs738409 genotype and diabetes identified patients with NAFLD currently considered indeterminate risk (FIB4 1.3-2.67) who had a similar risk of cirrhosis as those considered high-risk (FIB4 >2.67). PNPLA3 genotyping may improve prognostication and allow for prioritization of intensive intervention.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chen VL, Oliveri A, Miller MJ, et al. PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis. Gastroenterology. 2023. PMID: 36758837. doi:10.1053/j.gastro.2023.01.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。